Journal
MOLECULAR PHARMACEUTICS
Volume 10, Issue 3, Pages 793-812Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp3005325
Keywords
dendrimer; theranostics; prostate cancer; molecular imaging; drug delivery
Funding
- National Institutes of Health [R01CA159144]
- Prostate Cancer Research Program of the United States Army Medical Research and Materiel Command [W81XWH-12-1-0336P1, X.S., W81XWH-12-1-0336P2]
Ask authors/readers for more resources
Dendrimers are a class of structurally defined macromolecules featured with a central core, a low-density interior formed by repetitive branching units, and a high-density exterior terminated with surface functional groups. In contrast to their polymeric counterparts, dendrimers are nanosized and symmetrically shaped, which can be reproducibly synthesized on a large scale with monodispersity. These unique features have made dendrimers of increasing interest for drug delivery and other biomedical applications as nanoscaffold systems. Intended to address the potential use of dendrimers for the development of theranostic agents, which combines therapeutics and diagnostics in a single entity for personalized medicine, this review focuses on the reported methodologies of using dendrimer nanoscaffolds for targeted imaging and therapy of prostate cancer. Of particular interest, relevant chemistry strategies are discussed due to their important roles in the design and synthesis of diagnostic and therapeutic theranostic agents, targeted or nontargeted. Given the developing status of nanoscaffolded potential hurdles are discussed along with the examples representing current advances. dendrimer-based nanoconugates and potential theranostics, major challenges and potential hurdles are discussed along with the examples representing current advances.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available